Bruker–JPMorgan Chase: investor conference, 202201 supply service Bruker presents at JP Morgan Healthcare Conference 2022

	Period	2022-01-10
	Partner, 1st	Bruker Corporation (Nasdaq: BRKR)
	Group	Bruker (Group)
	Partner, 2nd	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 40th Annual Healthcare Conference 2022 DIGITAL
	Product 2	analytical instrument
	Person	Laukien, Frank H. (Bruker 201204 President + CEO)
	Person 2	Herman, Gerald N. (Bruker Corp 201806– CFO before Interim CFO joined 12/16 as VP + Corp Controller before Parexel)

Bruker Corporation. (1/4/22). "Press Release: Bruker Corporation to Present at the 40th Annual J.P. Morgan Healthcare Conference". Billerica, MA.

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 40th annual J.P. Morgan Healthcare Conference, to be held virtually on January 10-13, 2022. Frank Laukien, Chairman, President & CEO and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 10th, 2022 at 9:00 AM Eastern Standard Time.

A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Investor Contact:
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com